User profiles for G. Remuzzi
remuzzi g*Istituto di Ricerche Farmacologiche Mario Negri Verified email at marionegri.it Cited by 377833 |
[HTML][HTML] COVID-19 and Italy: what next?
… We read with interest the Health Policy piece 1 by Remuzzi and Remuzzi regarding the
COVID-19 epidemic in Italy. Italy is showing us how a developed country that has never tackled …
COVID-19 epidemic in Italy. Italy is showing us how a developed country that has never tackled …
Pathophysiology of progressive nephropathies
G Remuzzi, T Bertani - New England Journal of Medicine, 1998 - Mass Medical Soc
In patients with renal diseases characterized by proteinuria, the initial insult to the kidney is
usually followed by a progressive decline in the glomerular filtration rate. This decline has …
usually followed by a progressive decline in the glomerular filtration rate. This decline has …
[HTML][HTML] Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis
Background People of Sub Saharan Africa (SSA) and South Asians(SA) ethnic minorities
living in Europe have higher risk of stroke than native Europeans(EU). Study objective is to …
living in Europe have higher risk of stroke than native Europeans(EU). Study objective is to …
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
…, D Ranganathan, JT Rehm, DB Rein, G Remuzzi - The lancet, 2012 - thelancet.com
Background Reliable and timely information on the leading causes of death in populations,
and how these are changing, is a crucial input into health policy debates. In the Global …
and how these are changing, is a crucial input into health policy debates. In the Global …
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
Background The benefits of reducing blood pressure on the risks of major cardiovascular
disease are well established, but uncertainty remains about the comparative effects of different …
disease are well established, but uncertainty remains about the comparative effects of different …
[HTML][HTML] Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
…, AW McMahon, HH Parving, G Remuzzi… - … England Journal of …, 2009 - Mass Medical Soc
Background Statins reduce the incidence of cardiovascular events in patients at high
cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis …
cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis …
[HTML][HTML] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
… (measured in milligrams per liter) to urinary creatinine (measured in grams per liter) from
a first morning specimen of at least 300 (or a rate of urinary protein excretion of at least 0.5 g …
a first morning specimen of at least 300 (or a rate of urinary protein excretion of at least 0.5 g …
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010
Background Measurement of the global burden of disease with disability-adjusted life-years
(DALYs) requires disability weights that quantify health losses for all non-fatal …
(DALYs) requires disability weights that quantify health losses for all non-fatal …
[HTML][HTML] The contribution of chronic kidney disease to the global burden of major noncommunicable diseases
Noncommunicable diseases (NCDs) are the most common causes of premature death and
morbidity and have a major impact on health-care costs, productivity, and growth. …
morbidity and have a major impact on health-care costs, productivity, and growth. …
[HTML][HTML] A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
…, P Parfrey, HH Parving, G Remuzzi… - … England Journal of …, 2009 - Mass Medical Soc
… hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with
rescue darbepoetin alfa when the hemoglobin level was less than 9.0 g per deciliter. The primary …
rescue darbepoetin alfa when the hemoglobin level was less than 9.0 g per deciliter. The primary …